Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

82.11 -0.35 (-0.42%)
Streaming Delayed Price Updated: 12:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Via ACCESSWIRE
News headline image
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
Via ACCESSWIRE
News headline image
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Via ACCESSWIRE
News headline image
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
Via ACCESSWIRE
News headline image
Protagonist Receives $34 Million from Warrant Exercises
Via ACCESSWIRE
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
Via Investor Brand Network
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
Via ACCESSWIRE
News headline image
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
News headline image
Protagonist Therapeutics to Present at Upcoming Investor Conferences
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
News headline image
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Via ACCESSWIRE
News headline image
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.